American Heart Association Launches Initiative to Improve Clinical Trial Access for Rare Heart Condition
The American Heart Association is addressing healthcare disparities by launching a comprehensive initiative to improve education, outreach, and access to clinical trials for transthyretin amyloid cardiomyopathy (ATTR-CM), focusing on underrepresented populations and emerging gene editing therapies.
The American Heart Association has announced a nationwide initiative designed to enhance access to clinical trials and gene editing therapies for transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive heart condition that disproportionately affects older adults and certain racial and ethnic groups.
ATTR-CM is characterized by a misshapen protein that accumulates in the heart, impeding its ability to pump blood effectively. The condition often goes undiagnosed and can lead to heart failure, making early detection and innovative treatments critical.
The multifaceted initiative aims to address significant healthcare disparities by developing comprehensive educational resources, creating a referral network, and supporting multidisciplinary provider education. By leveraging clinical data and conducting targeted outreach, the program seeks to identify and engage potentially eligible clinical trial participants who might otherwise be overlooked.
Dr. Michelle Kittleson, an American Heart Association volunteer, emphasized the importance of matching medical innovation with education and opportunity. The initiative will include national webinars, research assessments, and strategies designed to build trust and awareness among patients, families, and clinicians.
The first webinar, scheduled for June 18, will focus on understanding amyloidosis and emerging therapeutic frontiers, featuring experts in cardiology and gene therapy. This approach represents a significant step toward ensuring equitable access to cutting-edge cardiovascular research and treatment options.